Evaluating LIVTENCITY for treating CMV infection in transplant patients in South Korea

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to assess the safety and effectiveness of LIVTENCITY (Maribavir) in adults suffering from cytomegalovirus (CMV) infection following transplantation. Participants will have their data collected over approximately 20 weeks, with recommended visits to the study doctor around six times during this period. The study focuses on individuals who have had prior treatments for CMV that were ineffective or not tolerated. The goal is to understand how LIVTENCITY performs in a real-world clinical setting.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Participants with post-transplant CMV infection and/or disease who are refractory and/or resistant to one or more prior therapy including ganciclovir, valganciclovir, cidofovir or foscarnet.
* Participants with age greater than or equal to (\>=) 19 years.
* Initiate first treatment course with maribavir.
* Voluntarily consent to participate in the study.

Exclusion Criteria:

* Participants for whom LIVTENCITY Tablet (maribavir) is contraindicated as per product label.
* Participants previously treated with maribavir in any study or as marketed drug.
* Participants actively participating in other clinical trials of post-transplant CMV infection treatment or with other experimental treatments.

Where it's running

• The Catholic University of Korea, Seoul ST. Mary's Hospital
  Seoul, South Korea Recruiting

Study contacts

• Study coordinator: Takeda Contact
• Email: medinfoUS@takeda.com
• Phone: +1-877-825-3327

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Maribavir for CMV in people with lymphoma or multiple myeloma receiving bispecific antibodies

  This will test whether the oral antiviral maribavir can treat CMV reactivation in adults with lymphoma or multiple myeloma who are receiving bispecific antibody therapy.

  Recruiting Phase 2 Seoul National University Hospital · Seoul · NCT07014319

• Preventing CMV after receiving a CMV-positive donor kidney using daily antiviral pills or weekly blood monitoring

  This study will test whether taking daily antiviral pills for 200 days or doing weekly blood checks and treating only if the virus appears is better at preventing CMV disease in adults who get a kidney from a CMV-positive donor and are themselves CMV-negative.

  Recruiting at 6 sites Phase 3 University of California, San Francisco · San Francisco, California and 7 other locations · NCT06798909

• Comparing tests for diagnosing cytomegalovirus in patients with inflammatory bowel disease

  This study is testing different ways to diagnose cytomegalovirus in adults with inflammatory bowel disease who are having worse symptoms and need to be hospitalized.

  Recruiting IRCCS Azienda Ospedaliero-Universitaria di Bologna · Bologna, Bologna · NCT06793124

• Survey of Maribavir tablets for treating Cytomegalovirus infection

  This study is testing if Maribavir tablets can help people with Cytomegalovirus infection who haven't responded to other treatments, especially those who have had an organ transplant.

  Recruiting Takeda · Tokyo, Tokyo · NCT06577363

• Maribavir for CMV in adults with kidney failure after transplantation

  This project will see if maribavir is safe for adults with severe kidney failure (including people on dialysis) who develop CMV after a transplant by reviewing existing medical records.

  Recruiting at 9 sites Takeda · Anderlecht, Brussels Capital and 24 other locations · NCT06243731

• Maribavir treatment for CMV infection in children and adolescents after stem cell or organ transplant

  This study tests whether maribavir is safe and works to treat CMV infection in children and teenagers who have had a stem cell or solid organ transplant.

  Recruiting at 53 sites Phase 3 Takeda · Wilmington, Delaware and 52 other locations · NCT05319353

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.